112108-73-3

Usage

Uses

Used in Pharmaceutical Industry:
1-CHLORO-5-FLUORO-2-METHYL-4-NITRO-BENZENE is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its unique structure allows for further functionalization and modification, making it a key component in the development of new therapeutic agents.
Used as Ceritinib Intermediate:
Specifically, 1-CHLORO-5-FLUORO-2-METHYL-4-NITRO-BENZENE is utilized in the production of Ceritinib, a potent and selective anaplastic lymphoma kinase (ALK) inhibitor. Ceritinib is an important drug used in the treatment of non-small cell lung cancer (NSCLC) patients with ALK rearrangements. The compound's presence in the synthesis process highlights its significance in the development of targeted cancer therapies.

InChI:InChI=1/C7H5ClFNO2/c1-4-2-7(10(11)12)6(9)3-5(4)8/h2-3H,1H3

Upstream product

• 452-73-3 2-chloro-4-fluorotoluene 
• 452-84-6 3-amino-4-fluorotoluene 

Downstream Products

• 862874-11-1 C₁₇H₂₃ClN₂O₅ 
• 862874-07-5 C₁₁H₁₅ClN₂O₃ 
• 864272-40-2 C₁₂H₁₈ClN₃O₂ 
• 116759-33-2 4-chloro-2-fluoro-5-methylaniline 
• 864272-42-4 C₁₅H₁₉ClN₂O₄ 
• 864272-41-3 C₁₁H₁₃ClN₂O₃ 
• 862874-04-2 C₁₅H₂₁ClN₂O₅ 
• 862874-00-8 C₁₇H₁₃ClN₂O₅ 
• 862874-06-4 C₁₃H₁₇ClN₂O₃ 

Relevant academic research and scientific papers

Regiospecific Oxidative Nitration of 3,4-Dihydro-6,7-disubstituted Quinoxalin-2(1H)-ones Gives 1,4-Dihydro-5-nitro-6,7-disubstituted Quinoxaline-2,3-diones, Potent Antagonists at the NMDA/Glycine Site

The regiospecific oxidative nitration of 3,4-dihydro-6,7-disubstituted quinoxalin-2(1H)-ones (15a-h, 20) utilizing fuming nitric acid in TFA gave 1,4-dihydro-5-nitro-6,7-disubstituted quinoxaline-2,3-diones (6a-i), respectively, in good yields.Compounds 15a-h were prepared from commercially available 1-halo-3,4-disubstituted benzenes 12a-h in three steps.These were nitration, nucleophilic substitution of the halogen ortho to the nitro group with sodium glycinate, and finally, reduction of the nitro group and concomitant cyclization.Compound 20 was prepared from 16 by a different route involving alkylation of substituted o-nitroaniline 18.The final oxidative nitration yields a single, predictable nitro isomer and is a significant improvement over the direct nitration of 6,7-disubstituted quinoxaline-2,3-diones.

Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model

Anaplastic lymphoma kinase (ALK) is an attractive therapeutic target for the treatment of non-small cell lung cancer (NSCLC). Within our ALK drug discovery program, we identified novel deuterated 2,4-diarylamino pyrimidine compounds as potent ALK inhibitors. The compound 11 showed better in vitro activity and in vivo efficacy with good pharmacokinetic profile. In vivo efficacy of compound 11 was better than standard drug ceritinib in NCI-H2228 xenograft mice model.

HYDRATE OF 2-ISOPROPOXY-5-METHYL-4-(PIPERIDIN-4-YL) ANILINE DIHYDROCHLORIDE, PREPARATION METHOD AND USE OF THE SAME

The present invention relates to 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride monohydrate and a preparation method of the same. The 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride monohydrate has a very good crystal form and is well suitable for recrystallization purification; further, the effect of impurity removal effect is very good, and any single impurity can be controlled less than 0.1%.

ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF

An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.

Preparation color Switzerland for Nepal new intermediate and its preparation method

The invention relates to intermediates, namely a compound 1 of a formula (1) as shown in the specification and a compound 2 of a formula (2) as shown in the specification, for preparing ceritinib, or a chemically acceptable salt of the compound 2, wherein R represents the benzylic group of saturated or unsaturated aromatic ring methylene or heteroaromatic ring methylene, and X represents a halogen. The invention relates to a method for preparing a compound 4 by use of the new intermediates, namely the compound 1 and the compound 2, wherein the step of reduction from the compound 1 to the compound 2 is performed by use of a hydroboron or a composition thereof and an alcohol solvent; the compound 2 is reduced by use of a catalytic hydrogenation or transfer hydrogenation method to generate the compound 4. The route of preparing the compound 4 by use of the compound 1 and the compound 2 has the advantages that the chemical reduction step is combined with a catalytic hydrogenation, the use of expensive platinum dioxide is avoided and the cost of synthesizing the intermediate 4 of the ceritinib is effectively reduced.

SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

Novel kinase inhibitors

The present invention relates to a novel kinase inhibitor useful as a medicine for tumor, nerve disorder and mental illness. The purpose of the present invention is to provide a compound having improved blood-aqueous barrier penetrability to neurodegenerative diseases that cancer spreads to brain or progresses in brain. To this end, provided is a compound represented by chemical formula 1 or a pharmaceutically allowable salt thereof.COPYRIGHT KIPO 2017

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl) phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials

The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of Formula (I) and salts and solvates are provided; wherein R, R5, R6 and Q are defined as in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.